论文部分内容阅读
非上市生物制药公司KaloBios近日宣布,诺华研究基金会基因研究所(GNF)与诺华已完成一项humaneer(TM)项目;Humaneer(TM)是一种用以治疗未公开目标的抗体。作为研制该工程人体抗体治疗剂的回报,KaloBios获得了研究费用,同时在临床试验成功完成时,KaloBios还将获得分期付款和权利金。公司宣布已开始执行第二个范围更大的合同;但两个合同的具体条款均未公布。基于第一份合同,GNF亲合性强、潜力大的非人体抗体候选药物为KaloBios的humaneer(TM)。由KaloBios提供的humaneered(TM)抗体符合或超过GNF与诺华定义的可获得成功付费的标准。 KaloBios首席执行官Geoffrey Yarranton博士对此指出,很高兴GNF与诺华将KaloBios视为其抗体开发引擎的一部分和得力的合作伙伴;KaloBios亦将致力于帮助GNF与诺华制造出最佳的人体抗体治
The unlisted biopharmaceutical company KaloBios announced recently that it has completed a humaneer (TM) project with the Novartis Research Foundation Genomics Institute (GNF) and Novartis, an antibody that targets undeclared targets. As a reward for developing a therapeutic for this engineered human antibody, KaloBios received the research cost, and KaloBios will also be paid installments and royalties when the clinical trial is successfully completed. The company announced that it has begun to implement the second larger contract; however, the specific terms of both contracts were not announced. Based on the first contract, GNF is a humaneer (TM) of KaloBios, a non-human antibody candidate with strong affinity and potential. The humaneered (TM) antibodies provided by KaloBios meet or exceed the criteria for achieving successful payments defined by GNF and Novartis. Dr. Geoffrey Yarranton, CEO of KaloBios, pointed out in this connection that GNF and Novartis are considering KaloBios as part of their antibody development engine and a competent partner; KaloBios will also work to help GNF and Novartis create the best human antibody management